BG63544B1 - Дихидратни соли на 5-(2-(4-(1,2-бензизотиазол-3- ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)-индол- 2-он (= ципразидон), мезилат, получаванетоим и използуването им като антагонист на допаминd2 - Google Patents
Дихидратни соли на 5-(2-(4-(1,2-бензизотиазол-3- ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)-индол- 2-он (= ципразидон), мезилат, получаванетоим и използуването им като антагонист на допаминd2 Download PDFInfo
- Publication number
- BG63544B1 BG63544B1 BG102892A BG10289298A BG63544B1 BG 63544 B1 BG63544 B1 BG 63544B1 BG 102892 A BG102892 A BG 102892A BG 10289298 A BG10289298 A BG 10289298A BG 63544 B1 BG63544 B1 BG 63544B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- common
- mesylate
- benzisothiazol
- chloro
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1675796P | 1996-05-07 | 1996-05-07 | |
PCT/IB1997/000393 WO1997042191A1 (en) | 1996-05-07 | 1997-04-10 | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist |
Publications (2)
Publication Number | Publication Date |
---|---|
BG102892A BG102892A (en) | 1999-09-30 |
BG63544B1 true BG63544B1 (bg) | 2002-04-30 |
Family
ID=21778804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG102892A BG63544B1 (bg) | 1996-05-07 | 1998-11-03 | Дихидратни соли на 5-(2-(4-(1,2-бензизотиазол-3- ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)-индол- 2-он (= ципразидон), мезилат, получаванетоим и използуването им като антагонист на допаминd2 |
Country Status (41)
Country | Link |
---|---|
US (1) | US6245765B1 (es) |
EP (1) | EP0918772B1 (es) |
JP (1) | JP3494659B2 (es) |
KR (1) | KR100333215B1 (es) |
CN (1) | CN1091769C (es) |
AP (1) | AP765A (es) |
AR (1) | AR007004A1 (es) |
AT (1) | ATE278689T1 (es) |
AU (1) | AU731267B2 (es) |
BG (1) | BG63544B1 (es) |
BR (1) | BR9709889A (es) |
CA (1) | CA2252898C (es) |
CO (1) | CO4940466A1 (es) |
CZ (1) | CZ289215B6 (es) |
DE (1) | DE69731094T2 (es) |
DK (1) | DK0918772T3 (es) |
DZ (1) | DZ2222A1 (es) |
EA (1) | EA001190B1 (es) |
EG (1) | EG24076A (es) |
ES (1) | ES2229342T3 (es) |
GT (1) | GT199700052A (es) |
HK (1) | HK1017892A1 (es) |
HR (1) | HRP970236B1 (es) |
ID (1) | ID16867A (es) |
IL (1) | IL126591A (es) |
IS (1) | IS2080B (es) |
MA (1) | MA24171A1 (es) |
MY (1) | MY119997A (es) |
NO (1) | NO312514B1 (es) |
NZ (1) | NZ332218A (es) |
OA (1) | OA10909A (es) |
PL (1) | PL188330B1 (es) |
PT (1) | PT918772E (es) |
SI (1) | SI0918772T1 (es) |
SK (1) | SK282837B6 (es) |
TN (1) | TNSN97074A1 (es) |
TR (1) | TR199802240T2 (es) |
TW (1) | TW491847B (es) |
UA (1) | UA46840C2 (es) |
WO (1) | WO1997042191A1 (es) |
ZA (1) | ZA973876B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
UA57734C2 (uk) | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
NZ551012A (en) * | 2000-06-02 | 2008-04-30 | Pfizer Prod Inc | Use of S-methyl-dihydro-ziprasidone administered via either the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal or topical routes in doses ranging from 0.5 to 500 mg per day |
UY27668A1 (es) * | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
US20040048876A1 (en) * | 2002-02-20 | 2004-03-11 | Pfizer Inc. | Ziprasidone composition and synthetic controls |
JP2006528676A (ja) | 2003-05-16 | 2006-12-21 | ファイザー・プロダクツ・インク | 非定形型抗精神病薬と、gaba調節薬及び/又は抗痙攣薬の治療上の組合せ |
WO2005016325A2 (en) * | 2003-06-03 | 2005-02-24 | Teva Pharmaceutical Industries Ltd. | CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF |
WO2005040160A2 (en) | 2003-10-24 | 2005-05-06 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
MXPA06013163A (es) * | 2004-05-11 | 2007-02-13 | Pfizer Prod Inc | Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b. |
CA2467538C (en) | 2004-05-14 | 2010-08-24 | Apotex Pharmachem Inc. | New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same |
CA2471219A1 (en) | 2004-06-14 | 2005-12-14 | Apotex Pharmachem Inc. | Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) |
US7777037B2 (en) * | 2004-10-27 | 2010-08-17 | Dr. Reddy's Laboratories Limited | Ziprasidone process |
US7910577B2 (en) * | 2004-11-16 | 2011-03-22 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
CA2591670A1 (en) * | 2005-02-11 | 2006-08-17 | Teva Pharmaceutical Industries Ltd. | Process of preparing ziprasidone mesylate |
CA2593497A1 (en) * | 2005-02-11 | 2006-08-17 | Judith Aronhime | Amorphous ziprasidone mesylate |
JP2008531721A (ja) * | 2005-03-03 | 2008-08-14 | エラン・ファルマ・インターナショナル・リミテッド | 複素環式アミド誘導体のナノ粒子状組成物 |
ITMI20050346A1 (it) | 2005-03-07 | 2006-09-08 | Dipharma Spa | Forma solida di ziprasidone cloridrato |
CA2500667C (en) | 2005-03-11 | 2013-01-15 | Apotex Pharmachem Inc. | Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions |
CA2599391A1 (en) * | 2005-03-14 | 2006-09-21 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of ziprasidone mesylate |
US20060270685A1 (en) * | 2005-03-14 | 2006-11-30 | Judith Aronhime | Anhydrous ziprasidone mesylate and a process for its preparation |
ITMI20052216A1 (it) * | 2005-11-18 | 2007-05-19 | Dipharma Spa | Procedimento per la preparazione di ziprasidone |
WO2008143960A1 (en) * | 2007-05-18 | 2008-11-27 | Scidose Llc | Ziprasidone formulations |
WO2009156889A1 (en) * | 2008-06-25 | 2009-12-30 | Pfizer Inc. | Diaryl compounds and uses thereof |
JP5893616B2 (ja) * | 2010-10-18 | 2016-03-23 | 大日本住友製薬株式会社 | 注射用徐放性製剤 |
SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX173362B (es) | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
US5359068A (en) | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
PL188164B1 (pl) | 1996-05-07 | 2004-12-31 | Pfizer | Trihydrat metanosulfonianu 5-{2-[4-1,2-benzizotiazol-3-ilo)-1-piperazynylo]etylo}-6-chloro-1,3-dihydro-2H-indol-2-onu i środek farmaceutyczny |
-
1997
- 1997-04-01 TW TW086104173A patent/TW491847B/zh not_active IP Right Cessation
- 1997-04-10 CZ CZ19983493A patent/CZ289215B6/cs not_active IP Right Cessation
- 1997-04-10 PL PL97329884A patent/PL188330B1/pl unknown
- 1997-04-10 DK DK97914520T patent/DK0918772T3/da active
- 1997-04-10 IL IL12659197A patent/IL126591A/en not_active IP Right Cessation
- 1997-04-10 EA EA199800912A patent/EA001190B1/ru not_active IP Right Cessation
- 1997-04-10 CA CA002252898A patent/CA2252898C/en not_active Expired - Lifetime
- 1997-04-10 UA UA98115905A patent/UA46840C2/uk unknown
- 1997-04-10 DE DE69731094T patent/DE69731094T2/de not_active Expired - Lifetime
- 1997-04-10 TR TR1998/02240T patent/TR199802240T2/xx unknown
- 1997-04-10 WO PCT/IB1997/000393 patent/WO1997042191A1/en active IP Right Grant
- 1997-04-10 CN CN97194244A patent/CN1091769C/zh not_active Expired - Fee Related
- 1997-04-10 SI SI9730676T patent/SI0918772T1/xx unknown
- 1997-04-10 US US09/180,455 patent/US6245765B1/en not_active Expired - Lifetime
- 1997-04-10 JP JP53967297A patent/JP3494659B2/ja not_active Expired - Lifetime
- 1997-04-10 PT PT97914520T patent/PT918772E/pt unknown
- 1997-04-10 ES ES97914520T patent/ES2229342T3/es not_active Expired - Lifetime
- 1997-04-10 EP EP97914520A patent/EP0918772B1/en not_active Expired - Lifetime
- 1997-04-10 BR BR9709889A patent/BR9709889A/pt not_active Application Discontinuation
- 1997-04-10 NZ NZ332218A patent/NZ332218A/en unknown
- 1997-04-10 KR KR1019980708960A patent/KR100333215B1/ko not_active IP Right Cessation
- 1997-04-10 SK SK1508-98A patent/SK282837B6/sk not_active IP Right Cessation
- 1997-04-10 AU AU21747/97A patent/AU731267B2/en not_active Ceased
- 1997-04-10 AT AT97914520T patent/ATE278689T1/de not_active IP Right Cessation
- 1997-04-29 GT GT199700052A patent/GT199700052A/es unknown
- 1997-04-29 CO CO97022872A patent/CO4940466A1/es unknown
- 1997-04-30 AP APAP/P/1997/000976A patent/AP765A/en active
- 1997-05-04 EG EG37997A patent/EG24076A/xx active
- 1997-05-05 AR ARP970101856A patent/AR007004A1/es unknown
- 1997-05-05 ID IDP971492A patent/ID16867A/id unknown
- 1997-05-06 DZ DZ970069A patent/DZ2222A1/fr active
- 1997-05-06 ZA ZA973876A patent/ZA973876B/xx unknown
- 1997-05-06 MA MA24595A patent/MA24171A1/fr unknown
- 1997-05-06 TN TNTNSN97074A patent/TNSN97074A1/fr unknown
- 1997-05-06 MY MYPI97001989A patent/MY119997A/en unknown
- 1997-05-07 HR HR970236A patent/HRP970236B1/xx not_active IP Right Cessation
-
1998
- 1998-10-20 IS IS4874A patent/IS2080B/is unknown
- 1998-10-30 OA OA9800206A patent/OA10909A/fr unknown
- 1998-11-03 BG BG102892A patent/BG63544B1/bg unknown
- 1998-11-06 NO NO19985194A patent/NO312514B1/no unknown
-
1999
- 1999-07-12 HK HK99102953A patent/HK1017892A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG63544B1 (bg) | Дихидратни соли на 5-(2-(4-(1,2-бензизотиазол-3- ил)-1-пиперазинил)-етил)-6-хлоро-1,3-дихидро-2(1н)-индол- 2-он (= ципразидон), мезилат, получаванетоим и използуването им като антагонист на допаминd2 | |
AP838A (en) | Mesylate trihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-y1)-1-piperaziny1)-ethy1) -6-chloro-1,3-dihydro-2h-indol-2-one. | |
KR0163186B1 (ko) | (1,2,3,4-테트라하이드로-9-아크리딘이미노)사이클로헥산 카복실산 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도 | |
PL185709B1 (pl) | Nowy monohydrat polimorfu II 6-N-(L-Ala-L-Ala)-trowafloksacyny i środek farmaceutyczny | |
MXPA98009242A (es) | Sal mesilato trihidrato de 5-(-2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona | |
NZ508304A (en) | Mesylate dihydrate salt of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one ( ziprasidone) useful as dopamine D2 antagonist |